TreeFrog Therapeutics

TreeFrog Therapeutics is a clinical-stage biotech company pioneering scalable manufacturing of iPS-derived cell therapies through its proprietary C-Stem™ technology platform. The C-Stem™ system uses biomimetic encapsulation to generate over 1,000 capsules per second in GMP-compliant conditions, enabling production of 15 billion cells per batch in bioreactors up to 10 liters — unlocking commercial-scale manufacturing previously unachievable in cell therapy. The company's lead program targets Parkinson's Disease, with a first-in-human trial planned by 2026, alongside discovery programs for liver disease. TreeFrog also out-licenses the C-Stem™ platform to pharmaceutical partners. Founded in 2018 in Bordeaux, France, the company has raised $82 million, employs over 130 people, and holds 30 patent families protecting its stem cell innovations.